States sue 23andMe over genetic data sales

Twenty-seven states and the District of Columbia are suing 23andMe, which filed for Chapter 11 bankruptcy in March, over its plans to potentially sell customers' genetic data without explicit consent. The lawsuit, filed in U.S. Bankruptcy Court, aims to prevent the company from auctioning off sensitive information collected from over 15 million consumers. The legal action follows Regeneron Pharmaceuticals' proposed $256 million purchase of 23andMe and concerns raised by House lawmakers regarding data privacy and deletion capabilities.

Analysis

Biotechnology firm 23andMe, which filed for Chapter 11 bankruptcy in March, is now facing a significant legal challenge from twenty-seven states and the District of Columbia. The lawsuit, filed in U.S. Bankruptcy Court, contests the company's potential plans to auction personal genetic information from its database of over 15 million consumers without obtaining explicit individual consent. This legal action introduces a substantial complication to 23andMe's bankruptcy proceedings and its proposed acquisition by Regeneron Pharmaceuticals for $256 million. While Regeneron has stated its intention to comply with existing privacy policies and laws regarding the data, the lawsuit underscores the contentious nature of monetizing such sensitive assets. The situation is further compounded by an ongoing investigation by House lawmakers, initiated a month after the bankruptcy filing, concerning data privacy and users' ability to delete their information. The overall sentiment surrounding this development is "strongly negative" (-0.75 sentiment score) with a "pessimistic" tone, and it carries a moderate market impact score of 0.55, reflecting concerns over data privacy, regulatory oversight, and the legal implications for companies handling genetic data.

Key Decisions for Investors

• The lawsuit against 23andMe significantly complicates its bankruptcy proceedings and the potential valuation of its data assets, creating substantial uncertainty for any stakeholders involved in the resolution of its Chapter 11 case.
• Investors in Regeneron Pharmaceuticals (REGN) should closely monitor this litigation, as it poses a material risk to its $256 million acquisition of 23andMe, potentially impacting the deal's terms, the value of the acquired genetic database, or necessitating more stringent data handling protocols.
• This event signals heightened regulatory and legal scrutiny over genetic data privacy, which could affect future M&A valuations, operational costs, and compliance risks for companies in the broader biotech and consumer genetics industries.